Nanobiotix

NBTXPhase 2

Nanobiotix is a French biotechnology company developing novel nanotherapeutics that aim to revolutionize cancer treatment by enhancing the efficacy of radiotherapy. Its core technology involves hafnium oxide nanoparticles (NBTXR3) that, when activated by radiotherapy, produce a significant increase in tumor cell death and may stimulate an adaptive immune response. The company has achieved key milestones with positive Phase 3 results in soft tissue sarcoma and is advancing clinical programs across multiple solid tumor indications, supported by strategic partnerships with global leaders like Johnson & Johnson and LianBio.

Market Cap

$1.4B

Employees

100-200

Focus

Biotech

NBTX · Stock Price

USD 29.03+22.03 (+314.48%)

Historical price data

AI Company Overview

Technology Platform

Proprietary nanoparticle platform using high atomic number hafnium oxide (NBTXR3) to physically amplify the dose of radiotherapy within injected tumors, increasing cancer cell death and potentially stimulating an anti-tumor immune response.

Pipeline Snapshot

3 drugs in pipeline

Drug	Indication	Stage
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRT	Prostate Cancer	Phase 1/2
NBTXR3	Locally-Advanced Non-Small Cell Lung Cancer	Phase 1/2
NBTXR3 + Nivolumab + Pembrolizumab	Radiotherapy	Phase 1

Funding History

Total raised: $30M

IPOUndisclosedUndisclosedJun 15, 2012

Series B$20MUndisclosedJun 15, 2011

Series A$10MUndisclosedJun 15, 2008

Opportunities

The primary growth opportunity lies in the successful approval and commercialization of NBTXR3 for head and neck cancer, which would validate the platform and generate initial revenue.

Significant upside exists in expanding into combination regimens with immunotherapy for large cancer indications like NSCLC, and in leveraging the platform's tumor-agnostic potential to enter new radiotherapy-treated cancer markets globally through partnerships.

Risk Factors

Key risks include the failure of the pivotal Phase 3 trial in head and neck cancer, which would jeopardize the company's lead program.

Additional risks are regulatory hurdles for a novel therapeutic class, challenges in commercial adoption by physicians, potential future competition, and the need for future capital raises if clinical timelines extend.

Competitive Landscape

Nanobiotix faces limited direct competition from other clinical-stage radioenhancers but competes indirectly with advanced radiotherapy delivery technologies and other immuno-oncology combination therapies. Its key differentiation is the first-in-class, physically-acting mechanism that amplifies a standard cancer treatment (radiotherapy) and its potential to generate a systemic immune response, validated by a major partnership with Johnson & Johnson.

Publications

Patents

Pipeline